0RDB.L

Oryzon Genomics S.A. [0RDB.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

0RDB.L Stock Summary

Top 10 Correlated ETFs

0RDB.L

Top 10 Correlated Stocks

0RDB.L

In the News

0RDB.L Financial details

Company Rating
-
Market Cap
123.59M
Income
-4.3M
Revenue
22.89M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
43
Optionable
No
Shortable
Yes
Earnings
03 May 2024
P/E
-25.52
Forward P/E
-
PEG
19.54
P/S
8.63
P/B
-12.73
P/C
-
P/FCF
-
Quick Ratio
1.14
Current Ratio
1.34
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.08
EPS next Y
-
EPS next Q
-
EPS this Y
-9.91%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
21.19%
Revenue last 5Y
18.28%
Revenue Q/Q
-
EPS Q/Q
-34%
-
-
-
-
SMA20
-13.44%
SMA50
73.13%
SMA100
72.05%
Inst Own
-
Inst Trans
-
ROA
-
ROE
50%
ROC
0.08%
Gross Margin
97%
Oper. Margin
-10%
Profit Margin
-30%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.602-2.395
52W High
+30%
52W Low
+160%
RSI
43.57
Rel Volume
3.93
Avg Volume
2.52K
Volume
9.9K
Perf Week
-5.11%
Perf Month
-20%
Perf Quarter
-
Perf Half Y
53.85%
-
-
-
-
Beta
0.638
-
-
Volatility
0.16%, 0.27%
Prev Close
-3.35%
Price
2.6
Change
-6.47%

Something similar

Top by Market Cap
V
BRK-A
TSLA
FB2A.DE
JPM
Top Correlated ETFs
HSTC.L
MCTS.L
EALU.MI
ALYU.L
CTEC.AS
Top Correlated Stocks
EXPRS2.ST
TEK.L
0QIH.L
1044.HK
2048.HK
Similar Market Cap
PCQ
8619.HK
K2H.WA
8277.HK
ALPA

Company Profile

Healthcare Medical - Pharmaceuticals
  • Volume Average 2.52K
  • Market Capitalization 123.59M
  • Employee 43
  • CEO Dr. Carlos Manuel Buesa Arjol
  • Headquarters Cornellà de Llobregat,ES
  • IPO Date 2016-12-15
  • Website https://www.oryzon.com

Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.